Media ReleasesImugene Limited

View All Imugene Limited News


Imugene appoints gastrointestinal cancer expert to Scientific Advisory Board

Sydney, Australia - 18 September 2018 – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced the appointment of Professor Tanios Bekaii-Saab of the Mayo Clinic College of Medicine and Science to its Scientific Advisory Board (SAB).

Imugene Managing Director and CEO Leslie Chong said, “Professor Bekaii-Saab is a recognised leader in gastrointestinal treatment and research. We look forward to the insights he will provide as the team at Imugene progresses its cancer immuno-therapy product pipeline.”

For further information please download PDF attached:
Download this document